Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
01/18/16
Corporate Presentation
12/15/15
FDA Resolution Overview

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
02/03/16SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
02/01/164Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
01/29/164Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
01/27/16SC 13G/AAn amendment to the SC 13G filingOther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
01/19/164Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
01/07/16Pacira Pharmaceuticals Reports Estimated Full-Year 2015 Total Revenue of $249.0 Million
PARSIPPANY, N.J., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced estimated EXPAREL® (bupivacaine liposome injectable suspension) and total revenues for the fourth quarter and full-year 2015.  These estimates, which are unaudited, are based on management’s preliminary financial analysis. “We are pleased with the strong finish to 2015 and the preliminary revenues that benefited from a solid fourth quarter—seasonally the strongest period of the yea... 
Printer Friendly Version
12/28/15Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
PARSIPPANY, N.J., Dec. 28, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 34th Annual J.P. Morgan Healthcare Conference at 4 p.m. PT (7 p.m. ET) on Monday, January 11, 2016, in San Francisco. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors &... 
Printer Friendly Version
12/15/15Pacira Pharmaceuticals Announces Favorable Resolution With U.S. Food and Drug Administration, Which Reaffirms the Broad Indication for EXPAREL®
-- Terms Include Labeling Changes to Reinforce that the Use of EXPAREL is not Limited to Pivotal Trial Surgical Models, and Formal FDA Rescission of 2014 Warning Letter – -- Conference Call Today at 8:30 am EST – PARSIPPANY, N.J., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has achieved an amicable resolution with the United States in its lawsuit filed on September 8, 2015, Pacira Pharmaceuticals, Inc. et al v. United States Food &am... 
Printer Friendly Version
11/24/15Pacira Pharmaceuticals, Inc. to Present at the 27th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 27th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET on Tuesday, December 1, in New York City. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” ... 
Printer Friendly Version
11/17/15New Survey Sheds Light on Prescription Drug Use Among Women After Surgery in the United States
Pacira and HealthyWomen Launch ‘Voice Your Choice’ Campaign Urging Patients to Know and Discuss Their Pain Control Options Before Surgery PARSIPPANY, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- One in every 15 patients who receive prescription painkillers (also called opioids or narcotics) following surgery ends up using these medications long-term,1,2 which can result in tolerance, dependence and addiction. According to a new national survey, a lack of doctor-patient communication about postsurg... 
Printer Friendly Version
11/11/15Pacira Pharmaceuticals, Inc. to Present at the Jefferies Autumn 2015 Global Healthcare Conference
PARSIPPANY, N.J., Nov. 11, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Jim Scibetta, president and chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies Autumn 2015 Global Healthcare Conference at 2:40 p.m. GMT (9:40 a.m. ET) on Thursday, November 19, in London. Mr. Scibetta is expected to present an overview of the company. A live audio webcast of the Pacira presentation can be accessed by visiting the “Inve... 
Printer Friendly Version
11/06/15New Study Finds Decreased Opioid Use, Hospital Stay and Readmission Rates With EXPAREL Following Knee Replacement Surgery
Data Presented at the Annual Meeting of the American Association of Hip and Knee Surgeons PARSIPPANY, N.J., Nov. 06, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced positive data on the use of EXPAREL® (bupivacaine liposome injectable suspension) as a postsurgical analgesic following total knee replacement surgery. The study, which compared the use of EXPAREL infiltration to the standard of care in 1,110 patients, found that EXPAREL was associated with sign... 
Printer Friendly Version
10/27/15Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
-- Total Revenues of $62.2 Million in Third Quarter -- -- EXPAREL® Net Revenues of $59.7 Million in Third Quarter -- -- Conference Call Today at 9 a.m. ET -- PARSIPPANY, N.J., Oct. 27, 2015 (GLOBE NEWSWIRE) --  Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2015. “Third quarter EXPAR... 
Printer Friendly Version
10/20/15Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President
-- Dave Stack Remains Chairman and Chief Executive Officer; Continues to Drive Commercial Strategy and Clinical Development of EXPAREL® and the DepoFoam® Pipeline -- -- Mr. Scibetta to Lead Tactical Execution of Operations -- PARSIPPANY, N.J., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that James S. Scibetta has been appointed president, effective October 20, 2015. In this capacity, Mr. Scibetta will oversee the day-to-day operations and ta... 
Printer Friendly Version
10/13/15Pacira Pharmaceuticals Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call
PARSIPPANY, N.J., Oct. 13, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (PCRX) today announced that financial results for the company’s third quarter ended September 30, 2015 will be released before the market opens on Tuesday, October 27, 2015. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Tuesday, October 27, 2015, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1... 
Printer Friendly Version
>> Access Older Press Releases
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com